title: Anterior chamber bleeding after laser peripheral iridotomy.
abstract: OBJECTIVE
  To our knowledge, this is the first study to describe the correlation of anterior chamber bleeding after laser peripheral iridotomy (LPI) and antiplatelet therapy.
  
  
  OBJECTIVE
  To determine the incidence and amount of anterior chamber bleeding after laser peripheral iridotomy in patients whose condition is suggestive of primary angle-closure glaucoma (PACS) who continued their antiplatelet or anticoagulant treatment before undergoing LPI compared with when they discontinued treatment.
  
  
  METHODS
  A prospective controlled trial.
  
  
  METHODS
  Patients with suspected bilateral primary angle-closure and no other ocular disease who take antiplatelet or anticoagulant medications regularly (from January 2010-October 2011) were enrolled.
  
  
  METHODS
  The incidence of anterior chamber bleeding with and without antiplatelet and anticoagulant therapy.
  
  
  RESULTS
  A total of 104 patients (208 eyes) participated in the study. Thirty-six eyes (34.6%) in the treated and untreated arms bled. The amount of bleeding did not differ significantly when the patient was on or off antiplatelet or anticoagulant treatment, nor did the immediate postprocedure mean intraocular pressure (P = .13). The type of antiplatelet or anticoagulant, total laser energy, age, sex, or color of irides were not risk factors for increased bleeding (P = .156 for all parameters).
  
  
  CONCLUSIONS
  No indication was noted for discontinuing these medications before a high-powered pulsed laser peripheral iridotomy.
authors.affiliation: Department of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel. shanigol2@walla.com
authors.forename: Shani
authors.initials: S
authors.lastname: Golan
authors.forename: Hani
authors.initials: H
authors.lastname: Levkovitch-Verbin
authors.forename: Gabi
authors.initials: G
authors.lastname: Shemesh
authors.forename: Shimon
authors.initials: S
authors.lastname: Kurtz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000473:pathology; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D005127:Eye Color; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000517:prevention & control*; D006068:Gonioscopy; D006801:Humans; D006988:Hyphema / Q000209:etiology*; D015994:Incidence; D007429:Intraocular Pressure; D032801:Iridectomy; D007498:Iris / Q000601:surgery; D053685:Laser Therapy; D053844:Lasers, Solid-State / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications; D011446:Prospective Studies; D012307:Risk Factors; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014065:Tonometry, Ocular; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin